Facial erythema of rosacea - aetiology, different pathophysiologies and treatment options

• Verfasst von: Steinhoff, Martin [VerfasserIn]
• Verfasst von: Schmelz, Martin [VerfasserIn]
• Verfasst von: Schauber, Jürgen [VerfasserIn]
• Titel: Facial erythema of rosacea - aetiology, different pathophysiologies and treatment options
• Verf.angabe: Martin Steinhoff, Martin Schmelz and Jürgen Schauber
• Jahr: 2016
• Jahr des Originals: 2015
• Umfang: 11 S.
• Fussnoten: Gesehen am 11.07.2019 ; Epub ahead of print Dec 30, 2015
• Titel Quelle: Enthalten in: Acta dermato-venereologica
• Ort Quelle: Uppsala : Acta Dermato-Venereologica, 1921
• Jahr Quelle: 2016
• Band/Heft Quelle: 96(2016), 5, Seite 579-586
• ISSN Quelle: 1651-2057
• DOI: doi:10.2340/00015555-2335
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1669011909

Abstract

Rosacea is a common chronic skin condition that displays a broad diversity of clinical manifestations. Although the pathophysiological mechanisms of the four subtypes are not completely elucidated, the key elements often present are augmented immune responses of the innate and adaptive immune system, and neurovascular dysregulation. The most common primary feature of all cutaneous subtypes of rosacea is transient or persistent facial erythema. Perilesional erythema of papules or pustules is based on the sustained vasodilation and plasma extravasation induced by the inflammatory infiltrates. In contrast, transient erythema has rapid kinetics induced by trigger factors independent of papules or pustules. Amongst the current treatments for facial erythema of rosacea, only the selective α2-adrenergic receptor agonist brimonidine 0.33% topical gel (Mirvaso®) is approved. This review aims to discuss the potential causes, different pathophysiologies and current treatment options to address the unmet medical needs of patients with facial erythema of rosacea.